Vasoactive drugs for the treatment of pulmonary hypertension associated with interstitial lung diseases: a systematic review.

ABSTRACT:

Objectives

Vasoactive drugs have exhibited clinical efficacy in addressing pulmonary arterial hypertension, manifesting a significant reduction in morbidity and mortality. Pulmonary hypertension may complicate advanced interstitial lung disease (PH-ILD) and is associated with high rates of disability, hospitalisation due to cardiac and respiratory illnesses, and mortality. Prior management hinged on treating the underlying lung disease and comorbidities. However, the INCREASE trial of inhaled treprostinil in PH-ILD has demonstrated that PH-ILD can be effectively treated with vasoactive drugs.

Methods

This comprehensive systematic review examines the evidence for vasoactive drugs in the management of PH-ILD.

Results

A total of 1442 pubblications were screened, 11 RCTs

SUBMITTER: Bongiovanni G 

PROVIDER: S-EPMC10941167 | biostudies-literature | 2024 Mar

REPOSITORIES: biostudies-literature